Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Gynae-Oncology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
R4018-ONC-1721A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer | |
|---|---|
| Local Project Reference: | 110877 |
| Principal Investigator: | Dr Rowan Miller |
| Drug Class/Treatment: | REGN4018 (MUC16xCD3 Bispecific Antibody) Monotherpay or Combination with Cemiplimab |
| Patient Population: | Recurrent Ovarian Cancer (advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
SL03-OHD-105 (REFMAL 721)Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers: An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers | |
|---|---|
| Local Project Reference: | 151942 |
| Principal Investigator: | Dr Rowan Miller |
| Drug Class/Treatment: | SL-172154 (Bi-Functional Fusion Protein targeting CD47) + Perylated Liposomal Doxorubicin or Mirvetuximab Soravtansine |
| Patient Population: | Platinum-Resistant Ovarian Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
BOUQUET (WO42178)A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors | |
|---|---|
| Local Project Reference: | 139231 |
| Principal Investigator: | Dr. Rowan Miller |
| Drug Class/ Treatment: | Platform trial of various Immunotherapy and Targeted Therapy Agents. |
| Patient Population: | Persistent Or Recurrent Rare Epithelial Ovarian Tumors |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
AZD6738 in Combination With Other Agents in Solid Malignancies (D5330C00004)A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies | |
|---|---|
| Local Project Reference: | 18/0067 |
| Principal Investigator: | Dr Rowan Miller |
| Drug Class/Treatment: | AZD6737 (Ceralasertib) (ATR Kinase Inhibitor)
|
| Patient Population: | Advanced Solid Tumours:
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
